Clinical

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women's Health Week and every week.

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.

This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.

New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.

A US-based discrete choice experiment survey found that patients with atopic dermatitis (AD) prioritize treatments that effectively control itching.

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection.

Immune checkpoint blockade therapy works by preventing the binding of checkpoint and partner proteins, thereby allowing T cells to continue their work of attacking and killing cancer cells.

While urologists and oncologists agreed on many barriers and facilitators of first-line treatment intensification for metastatic castrate-sensitive prostate cancer, there were also a number of differing beliefs, including whether there is enough clinical support.

In addition to her advanced age and obesity status, the patient had a history of pulmonary embolism managed with an inferior vena cava filter, increasing her risk of thrombosis.

Patients diagnosed with ovarian cancer (OC), particularly those older than 60 years or with a disease duration exceeding 5 years, had a higher incidence of subsequent dry eye disease (DED), suggesting a potential correlation between OC and DED.

A novel program utilizing an approach to defragment care for patients with end-stage kidney disease (ESKD) resulted in better patient outcomes.

Chris Pagnani, MD, medical director and founder of Rittenhouse Psychiatric Associates in Philadelphia, explains the importance of offering college students consistent care via telehealth while collaborating with their campus counseling centers.

The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.

Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Ascension Health was hit with a cyberattack; a new federal policy is aimed at integrating Medicare and Medicaid coverage; the CDC is planning to post data on influenza A found in wastewater in a public dashboard.

Risk assessments of drug-related problems for cardiac surgery patients can be conducted by implementing a framework for patient safety.

Speakers at the 2024 American Urological Association (AUA) annual meeting highlighted the innovations and advancements that are pushing the field of urology forward.

Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.

The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.

Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.

Pembrolizumab has existing indications in endometrial cancer.

Asking patients about their diet is important when evaluating for adult-onset asthma, allergic disease, and aspirin-exacerbated respiratory disease (AERD).

Research shows a high prevalence of cardiovascular-kidney-metabolic (CKM) syndrome among adults; tackling mental health and substance abuse nationwide; a delayed meeting allows for surveillance data collection to inform recommendations.

Celiac disease (CD) may independently increase mortality risk among patients with microscopic colitis (MC), indicating a potential association between the conditions.

Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.

This study introduces a novel "all-in-one" strategy combining CD7 chimeric antigen receptor T-cell therapy with haploidentical hematopoietic stem-cell transplantation, showing significant potential to improve survival and reduce toxicities in patients with relapsed or refractory CD7-positive hematologic cancers.

New therapies being developed are moving into earlier lines of therapy, with the idea that most patients with early-stage prostate cancer will progress and need additional therapy later.